RPG Life Sciences Limited
NSE: RPGLIFE BSE: RPGLIFE
NSE
2,179.20
-22.60 (-1.03%)
Prev Close
2201.8
Open Price
2201.8
Volume
10,217
Today Low / High
2170.7 / 2240
52 WK Low / High
1381 / 2974.95
Range
2,070 - 2,288
BSE
2,177.30
-19.95 (-0.91%)
Prev Close
2197.25
Open Price
2192.9
Volume
397
Today Low / High
2170 / 2236.75
52 WK Low / High
1382.55 / 2976.7
Range
2,068 - 2,286
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 2179.2 (target range: 2,070 - 2,288), reflecting a change of -22.6 (-1.02643%). On the BSE, it is listed at 2177.3 (target range: 2,068 - 2,286), showing a change of -19.95 (-0.90795%). The stock price is currently in decline on both exchanges, signaling a downtrend. If you're considering investing in this stock, it's important to monitor the situation closely.
21 Apr
2,201.80
-1.03%
17 Apr
2,195.10
0.31%
16 Apr
2,188.50
-0.16%
15 Apr
2,099.10
3.29%
11 Apr
2,005.00
2.94%
09 Apr
2,035.00
-3.22%
08 Apr
2,060.00
-1.03%
07 Apr
1,835.00
8.66%
04 Apr
2,277.75
-4.48%
03 Apr
2,308.00
0.19%
02 Apr
2,280.95
3.09%
01 Apr
2,281.55
-1.10%
28 Mar
2,233.95
2.13%
27 Mar
2,260.00
-0.74%
26 Mar
2,260.00
0.77%
25 Mar
2,326.55
-3.06%
24 Mar
2,355.05
-1.12%
RPG Life Sciences Limited Graph
RPG Life Sciences Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for RPG Life Sciences Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 2,179.20, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 2,177.30 | 2,199.07 | 1,979.17 - 2,418.98 |
| 2,220.85 | 1,776.68 - 2,665.02 | ||
| 2,242.62 | 1,569.83 - 2,915.40 | ||
| Bearish Scenario | 2,177.30 | 2,155.53 | 1,939.97 - 2,371.08 |
| 2,133.75 | 1,707.00 - 2,560.50 | ||
| 2,111.98 | 1,478.39 - 2,745.58 |
Overview of RPG Life Sciences Limited
ISIN
INE105J01010
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
21,233
Market Cap
36,041,821,488
Last Dividend
16
Official Website
IPO Date
2002-08-12
DCF Diff
-3,461.90
DCF
5,695
Financial Ratios Every Investor Needs
Stock Dividend of RPGLIFE
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2024-06-28 | June 28, 24 | 16 | 16 | 2024-06-28 | 2024-08-15 | |
| 2023-07-21 | July 21, 23 | 12 | 12 | 2023-07-21 | 2023-09-03 | |
| 2022-07-14 | July 14, 22 | 9.6 | 9.6 | 2022-07-15 | 2022-08-28 | |
| 2021-08-13 | August 13, 21 | 7.2 | 7.2 | 2021-08-17 | 2021-09-30 | |
| 2020-03-24 | March 24, 20 | 4 | 4 | 2020-03-26 | 2020-03-31 | 2020-03-11 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 577.48 Cr | 194.20 Cr | 383.28 Cr | 0.6637 | 7.59 Cr | 132.89 Cr | 229.23 Cr | 87.66 Cr | 53.00 | 136.35 Cr | 0.1518 |
| 2023-03-31 | 512.81 Cr | 170.87 Cr | 341.94 Cr | 0.6668 | 8.93 Cr | 18.17 Cr | 88.10 Cr | 67.64 Cr | 40.90 | 108.33 Cr | 0.1319 |
| 2022-03-31 | 437.16 Cr | 150.21 Cr | 286.95 Cr | 0.6564 | 8.97 Cr | 19.66 Cr | 70.74 Cr | 51.48 Cr | 31.13 | 90.24 Cr | 0.1178 |
| 2021-03-31 | 383.40 Cr | 137.64 Cr | 245.76 Cr | 0.6410 | 8.88 Cr | 15.17 Cr | 53.66 Cr | 40.00 Cr | 24.19 | 71.84 Cr | 0.1043 |
| 2020-03-31 | 369.15 Cr | 127.76 Cr | 241.39 Cr | 0.6539 | 9.33 Cr | 12.84 Cr | 42.95 Cr | 29.01 Cr | 17.54 | 55.57 Cr | 0.0786 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 19.72 Cr | 512.87 Cr | 138.02 Cr | 374.8500 Cr | 0.00 Cr | -19.72 Cr | 101.00 Cr | 181.81 Cr | 1.84 Cr | 0.00 Cr | 1.01 Cr | 130.9600 Cr |
| 2023-03-31 | 24.82 Cr | 419.35 Cr | 111.75 Cr | 307.6000 Cr | 0.01 Cr | -24.81 Cr | 95.05 Cr | 116.30 Cr | 31.88 Cr | 3.02 Cr | -91.56 Cr | 102.7800 Cr |
| 2022-03-31 | 56.94 Cr | 344.61 Cr | 88.84 Cr | 255.7700 Cr | 0.94 Cr | -56.00 Cr | 82.99 Cr | 100.09 Cr | 28.41 Cr | 3.13 Cr | -14.43 Cr | 80.1100 Cr |
| 2021-03-31 | 40.36 Cr | 303.39 Cr | 86.94 Cr | 216.4500 Cr | 2.02 Cr | -38.34 Cr | 58.33 Cr | 87.94 Cr | 24.53 Cr | 3.38 Cr | -1.25 Cr | 79.6900 Cr |
| 2020-03-31 | 0.54 Cr | 266.73 Cr | 90.16 Cr | 176.5700 Cr | 11.72 Cr | 11.18 Cr | 46.61 Cr | 91.00 Cr | 25.54 Cr | 3.33 Cr | 136.35 Cr | 82.5900 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 94.3600 Cr | -79.1500 Cr | -20.3100 Cr | 25.1300 Cr | -5.1000 Cr | 19.7200 Cr | -69.2300 Cr | 87.6600 Cr | -0.0100 Cr | -19.8500 Cr | -5.9500 Cr |
| 2023-03-31 | 90.8200 Cr | -105.8100 Cr | -17.1200 Cr | 58.0900 Cr | -32.1200 Cr | 24.8200 Cr | -32.7300 Cr | 91.6800 Cr | -0.2800 Cr | -15.8800 Cr | -12.0600 Cr |
| 2022-03-31 | 64.7500 Cr | -34.6600 Cr | -13.5100 Cr | 40.8000 Cr | 16.5800 Cr | 56.9400 Cr | -23.9500 Cr | 73.1700 Cr | -0.4200 Cr | -11.9100 Cr | -24.6600 Cr |
| 2021-03-31 | 58.2700 Cr | -7.9600 Cr | -10.4900 Cr | 49.7600 Cr | 39.8200 Cr | 40.3600 Cr | -8.5100 Cr | 53.5800 Cr | -9.0700 Cr | 0.0000 Cr | -11.7200 Cr |
| 2020-03-31 | 50.1700 Cr | -10.7000 Cr | -39.3000 Cr | 39.4300 Cr | 0.1700 Cr | 0.5400 Cr | -10.7400 Cr | 36.4500 Cr | -24.1300 Cr | -12.7700 Cr | -5.5700 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | 172.71 Cr | 56.11 Cr | 116.60 Cr | 0.6751 | 43.70 Cr | 34.93 Cr | 21.12 | 52.47 Cr | 0.2022 |
| 2024-09-30 | 172.21 Cr | 54.17 Cr | 118.04 Cr | 0.6854 | 40.62 Cr | 4.20 Cr | 2.54 | 20.57 Cr | 0.0244 |
| 2024-06-30 | 165.42 Cr | 93.04 Cr | 72.38 Cr | 0.4376 | 33.78 Cr | 26.76 Cr | 16.18 | 41.44 Cr | 0.1618 |
| 2024-03-31 | 126.99 Cr | 78.01 Cr | 48.98 Cr | 0.3857 | 16.23 Cr | 13.24 Cr | 8.01 | 20.72 Cr | 0.1043 |
| 2023-12-31 | 153.70 Cr | 48.17 Cr | 105.53 Cr | 0.6866 | 35.68 Cr | 26.46 Cr | 16.00 | 39.82 Cr | 0.1722 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2024-09-30 | 17.28 Cr | 110.45 Cr | 127.73 Cr | 0.00 Cr | 99.16 Cr | 330.17 Cr | 181.79 Cr | 554.37 Cr | 174.99 Cr |
| 2024-06-30 | -125.87 Cr | 251.74 Cr | 125.87 Cr | 0.00 Cr | 0.00 Cr | 125.87 Cr | 0.00 Cr | 0.00 Cr | -374.85 Cr |
| 2024-03-31 | 36.47 Cr | 90.15 Cr | 126.62 Cr | 51.58 Cr | 101.00 Cr | 298.09 Cr | 181.81 Cr | 512.87 Cr | 138.02 Cr |
| 2023-12-31 | -101.95 Cr | 203.90 Cr | 101.95 Cr | 0.00 Cr | 0.00 Cr | 101.95 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-09-30 | 22.32 Cr | 80.76 Cr | 103.08 Cr | 60.07 Cr | 100.57 Cr | 280.37 Cr | 139.77 Cr | 461.14 Cr | 125.40 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2024-06-30 | 26.76 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | 13.24 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-12-31 | 26.46 Cr | 8.28 Cr | 0.00 Cr | 0.00 Cr | 8.28 Cr | 31.29 Cr | 23.01 Cr | 0.00 Cr | 8.28 Cr |
| 2023-09-30 | 25.86 Cr | 8.46 Cr | 0.00 Cr | 0.00 Cr | 8.46 Cr | 23.01 Cr | 14.55 Cr | 0.00 Cr | 8.46 Cr |
| 2023-06-30 | 22.10 Cr | 8.42 Cr | 0.00 Cr | 0.00 Cr | 8.42 Cr | 33.91 Cr | 25.49 Cr | 0.00 Cr | 8.42 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,744.90 | ₹4,186,497,390,360.00 | ₹1,539,404.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹5,891.50 | ₹1,564,008,080,155.00 | ₹717,304.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,254.60 | ₹1,101,504,496,478.00 | ₹168,941.00 |
| Mankind Pharma Limited | MANKIND | ₹2,588.40 | ₹1,067,918,241,168.00 | ₹342,053.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,177.40 | ₹980,907,622,968.00 | ₹1,938,682.00 |
| Lupin Limited | LUPIN | ₹2,009.20 | ₹917,330,458,276.00 | ₹966,589.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹845.35 | ₹850,616,530,500.00 | ₹1,860,605.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,201.20 | ₹697,658,929,968.00 | ₹653,310.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,000.40 | ₹597,872,826,000.00 | ₹97,948.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,368.80 | ₹386,259,126,032.00 | ₹2,163,260.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,423.80 | ₹361,224,068,436.00 | ₹163,712.00 |
| Laurus Labs Limited | LAURUSLABS | ₹640.35 | ₹345,310,338,375.00 | ₹1,671,228.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,679.20 | ₹334,664,498,320.00 | ₹44,703.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,202.20 | ₹306,037,994,912.00 | ₹330,131.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,658.70 | ₹258,221,804,814.00 | ₹100,079.00 |
| Piramal Enterprises Limited | PEL | ₹1,039.85 | ₹234,462,986,345.00 | ₹552,041.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,401.40 | ₹227,698,028,558.00 | ₹264,593.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,727.50 | ₹218,187,500,000.00 | ₹13,476.00 |
| Eris Lifesciences Limited | ERIS | ₹1,382.90 | ₹188,299,218,053.00 | ₹81,150.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹13,136.00 | ₹168,533,566,400.00 | ₹53,273.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹849.65 | ₹167,009,863,405.00 | ₹223,768.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹829.80 | ₹148,625,361,828.00 | ₹383,129.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹915.95 | ₹145,893,560,183.00 | ₹228,298.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,906.70 | ₹144,931,500,763.00 | ₹146,966.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Granules India Limited | GRANULES | ₹480.20 | ₹116,469,494,344.00 | ₹1,207,487.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,223.50 | ₹86,706,866,654.00 | ₹3,571.00 |
| FDC Limited | FDC | ₹430.60 | ₹70,106,024,754.00 | ₹67,489.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹712.85 | ₹64,608,888,867.00 | ₹374,808.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹658.10 | ₹64,356,197,871.00 | ₹163,074.00 |
| Strides Pharma Science Limited | STAR | ₹640.75 | ₹59,053,256,433.00 | ₹243,236.00 |
| Innova Captab Limited | INNOVACAP | ₹915.85 | ₹52,409,452,141.00 | ₹37,786.00 |
| Hikal Limited | HIKAL | ₹423.80 | ₹52,254,857,850.00 | ₹371,223.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹152.84 | ₹49,599,942,480.00 | ₹505,473.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹633.90 | ₹44,630,236,620.00 | ₹75,809.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹799.75 | ₹40,562,604,224.00 | ₹101,985.00 |
| Sequent Scientific Limited | SEQUENT | ₹148.17 | ₹37,087,247,340.00 | ₹527,793.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,179.20 | ₹36,041,821,488.00 | ₹10,217.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹349.90 | ₹35,087,098,650.00 | ₹40,163.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹361.65 | ₹33,007,795,500.00 | ₹101,872.00 |
| Morepen Laboratories Limited | MOREPENLAB | ₹53.91 | ₹29,540,183,967.00 | ₹4,747,370.00 |
| Suven Life Sciences Limited | SUVEN | ₹127.13 | ₹27,723,712,024.00 | ₹173,057.00 |
| Alembic Limited | ALEMBICLTD | ₹105.35 | ₹27,051,965,791.00 | ₹436,085.00 |
| Solara Active Pharma Sciences Limited | SOLARA | ₹520.70 | ₹25,021,207,514.00 | ₹37,558.00 |
Key Executives
Vice President of Sales & Marketing (Main Division)
Mr. Samir Rane
Gender: male
Year Born:
Chief Human Resources Officer
Ms. Sheetal Gaba
Gender: female
Year Born:
MD & Director
Mr. Yugal Kishor Choturam Sikri
Gender: male
Year Born: 1957
Chief Financial Officer
Mr. Vishal Shah
Gender: male
Year Born:
Head of API Operations & Procurement
Mr. Kartick C. Patra
Gender: male
Year Born:
Site Head of International Formulation
Mr. Rajesh Chopra
Gender: male
Year Born:
Chief Quality Officer
Mr. Milind Gujar
Gender: male
Year Born:
Head of Legal, Compliance Officer & Company Secretary
Mr. Rajesh Shirambekar
Gender: male
Year Born:
FAQs about RPG Life Sciences Limited
Who is the CEO of the company?
The CEO is Mr. Yugal Kishor Choturam Sikri.
What is the current market price of the stock?
The current price is ₹2,179.20.
What is the 52-week price range?
The range is ₹1381-2974.95.
What is the market capitalization of the company?
The market capitalization is ₹3,604.18 crores.
What is the dividend yield?
The dividend yield is 0.73%.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 45.55.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of RPG Life Sciences Limited (ISIN: INE105J01010) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹3,604.18 crores and an average daily volume of 21,233 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹16.